期刊文献+

Akt磷酸化在A549细胞抵抗rsTRAIL蛋白诱导细胞凋亡的研究

Akt phosphorylation and mechanism of TRAIL-resistance in A549 cells
下载PDF
导出
摘要 目的:研究Akt磷酸化抵抗rsTRAIL蛋白诱导肺癌A549细胞株凋亡的作用机制。方法:rsTRAIL蛋白和哌立福新单独和联合作用于细胞株A549,Western blot检测A549细胞中Akt磷酸化水平变化、c-FLIPLL表达水平变化、caspase-8蛋白活化变化情况。流式细胞术进行细胞凋亡检测。MTT法检测A549细胞增殖率。结果:Western blot结果显示,rsTRAIL蛋白可以导致A549细胞中Akt磷酸化水平的增加,哌立福新能够抑制A549细胞中Akt的磷酸化水平及c-FLIPLL表达水平,增强A549细胞中caspase-8的活化。哌立福新能提升rsTRAIL蛋白诱导A549细胞的细胞凋亡率至(76.5±3.02)%和杀伤活性到(83.2±2.54)%。结论:Akt磷酸化是导致A549细胞对抵抗rsTRAIL诱导细胞凋亡的重要原因,抑制其活性可以促进rsTRAIL蛋白发挥抗NSCLC的活性。 Objective:To investigate mechanism of TRAIL-resistance in A549 cells ( a cell line of non-small cell lung carcino-ma cells) due to Akt phosphorylation .Methods:A549 cells were treated with Akt inhibitor Perifosine and rsTRAIL protein individual-ly and in combination.The expressions of Akt phosphorylation(p-Akt),c-FLIPLL and caspase-8 were detected by Western blot.The apoptotic rate of the A549 cells treated was detected by flow cytometry and the cell proliferation was evaluated by MTT assay .Results:A549 cells showed the increased level of Akt phosphorylation mediated by rsTRAIL protein .Treatment with the Akt inhibitor Perifosine induced a suppression of Akt activation in A 549 cells and a concomitant decrease in the expression of c-FLIPLL .As a result, Perifosine significantly enhanced TRAIL-induced apoptosis rate of (76.5±3.02)%and cytotoxic rate of (83.2 ±2.54)%by promoting the activ-ity of caspase-8.Conclusion:Akt activity promotes A549cells survival against TRAIL-induced apoptosis and that the cytotoxic effect of rsTRAIL protein can be enhanced by modulating the Akt phosphorylation in human non -small cell lung carcinoma cells .
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2014年第5期630-632,638,共4页 Chinese Journal of Immunology
基金 吉林省科技厅基础项目(No.201115201) 吉林省科技厅重点实验室项目(No.20122113) 吉林省卫生厅项目(No.20082036) 吉林省科技厅科技创新项目(No.20082102)的资助
关键词 A549细胞株 重组TRAIL蛋白 哌立福新 Akt A549 cells rsTRAIL protein Akt Perifosine
  • 相关文献

参考文献10

  • 1Bareschino MA, Schettino C, Rossi A, et al. Treatment of ad- vanced non small cell lung cancer[ J ]. J Thorac Dis, 2011,3 (2) : 122-133.
  • 2Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy[ J]. Trends Mol Med, 2013,19( 11 ) :685-694.
  • 3刘磊,方艳秋,许淑芬,谭岩.重组可溶性TRAIL的表达及其诱导A549和H460^(wt)细胞凋亡[J].吉林大学学报(医学版),2008,34(2):270-273. 被引量:5
  • 4Cretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strat- egies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway[ J]. Int J Biochem Cell Biol, 2007,39(2) :280-286.
  • 5谭岩,刘磊,方艳秋,蒋永兴.抑制c-FLIP_L表达增强rhTRAIL蛋白杀伤肺癌A549细胞的研究[J].中国免疫学杂志,2012,28(10):890-893. 被引量:3
  • 6Tazzari PL, Tabellini G, Ricci F, et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogen'ous leukemia cells [ J ]. Cancer Res, 2008, 68 ( 22 ) :9394-9403.
  • 7Papadimitrakopoulou V. Development of PI3K/AKT/mTOR path- way inhibitors and their application iN personalized therapy for non-small-cell lung cancer [ J ]. J Thorac Oncol, 2012,7 ( 8 ) : 1315-1326.
  • 8Willenas L, Tamburini J, Chapuis N, et al. PI3K and roTOR sig- naling pathways in cancer: new data on targeted therapies [ J]. Curr Oncol Rep, 2012,14(2) :129-138.
  • 9Pier Luigi Tazzari, Giovanna Tabellini, et al. Activity of recombi- nant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells [J]. Cancer Res ,2008,68: (22) :9394-9430.
  • 10A1 Sawah E, Chen X, Marchion DC, et al. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cispla- tin-induced growth arrest [J]. Gynecol Oneol, 2013, 131 ( 1 ) :207.

二级参考文献15

  • 1Lin ZH, Lei HZ , Cao P. Expression, purification, and in vitro refolding of soluble tumor necrosis factor related apoptosis inducing ligand [J]. Protein Exp Purif, 2007, 51: 276-282.
  • 2Zanca C, Garofalo M, Quintavalle C, et al. PED is overexpressed and mediates TRAIL resistance in human nonsmall cell lung cancer [J]. J Cell Mol Med, 2008, 15 (18): 1262-1270.
  • 3Ashkenazi A , Pal RC, Fong S, et al, Safety and antitumor activity of recombinant soluble Apo2 ligand [J]. Clin Invest, 1999, 104 (2): 155 -162.
  • 4Song jH, Tse MC, Hao C, et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosls-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells [J]. Cancer Res, 2007, 67 (14): 6946-6955.
  • 5Lacour S , Micheau O , Hammann A , et al. Chemotherapy enhances TNF-related apoptosisinducing ligand DISC assembly in HT29 human colon cancer cell [J]. Oncogene , 2003,22 (12) : 1807-1816.
  • 6Safa A R, Day T W, Wu C H. Cellular FLICE-like inhibitory protein (C-FLIP) : a novel target for cancer therapy [J]. CUff Cancer Drug Targets, 2008; 8 (1 ) :3746.
  • 7Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c- FLIP) signalling: a key regulator of receptor-mediated ap?optosis in physiologic context and in cancer [J J. Int J Biochem Cell BioI, 2010; 42{ 2) :210-213.
  • 8Sun S Y, Yue P, Zhou J Y et al, Overexpression of BCI2 blocks TNF -related-apoptosis-inducing ligand (TRAIL) -induced apoptosis in human lung cancer cells [J]. Biochem Biophys Res Commun, 2001 ; 280(3) : 788-798.
  • 9Ashkenazi A ,Pai R C, Fong S et al. Safety and antitumor activity of recombinant soluble Apo2 ligand [J J. J Clin Invest, 1999; 104 (2) : 155-]62.
  • 10Kim Y S, Jin H 0, Seo S K et al. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR) -dependent sutvivin expres?sion[ J]. Biochem Pharmacol, 201 I ;82 (3) :216-226.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部